Inventor

Bert Vogelstein

Inventor

Baltimore, MD, US

Overview

1993–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 207 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Qprimary

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms26%

C07KPeptides15%

A61KPreparations for medical, dental or toiletry purposes12%

G01NInvestigating or analysing materials by determining their chemical or physical properties12%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations10%

C12NMicroorganisms or enzymes8%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8%

A01KAnimal husbandry3%

Y10TTechnical subjects covered by former us classification1%

C12YEnzymes1%

PatentTitleYear

10,934,356Checkpoint blockade and microsatellite instability2021 10,894,987Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma2021 10,874,726Autoimmune antigens and cancer2020 10,869,926Suppression of myeloid derived suppressor cells and immune checkpoint blockade2020 10,870,890TERT promoter mutations in urothelial neoplasia2020 10,837,050Methods for beaming2020 10,837,064Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma2020 10,787,713Mutations of the PIK3CA gene in human cancers2020 10,787,712Consensus coding sequences of human breast and colorectal cancers2020 10,751,306Methods of treating liver fibrosis by administering 3-bromopyruvate2020 10,711,310Tert promoter mutations in gliomas and a subset of tumors2020 10,704,108Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma2020 10,704,105Mutations of the PIK3CA gene in human cancers2020 10,619,217Oligodendroglioma drive genes2020 10,617,723None2020 10,604,797Method and compositions for detection and enumeration of genetic variations2020 10,590,465Enrichment of nucleic acids by complementary capture2020 10,422,006Mutations of the PIK3CA gene in human cancers2019 10,150,991Methods for beaming2018 10,144,971Genes frequently altered in pancreatic neuroendocrine tumors2018 10,053,729Rapid aneuploidy detection2018 9,982,304ARID1A and PPP2R1A mutations in cancer2018 9,982,306Somatic mutations in ATRX in brain cancer2018 9,976,184Mutations in pancreatic neoplasms2018 9,970,058Digital amplification2018 9,957,572Personalized tumor biomarkers2018 9,926,606'Tyrosine kinome'2018 9,873,917Oligodendroglioma drive genes2018 9,737,487'Cyclodextrin compositions encapsulating a selective ATP inhibitor and uses thereof'2017 9,695,479'Medulloblastoma genes as targets for diagnosis and therapeutics'2017 9,670,527'Enrichment of nucleic acids by complimentary capture'2017 9,637,796'Differential identification of pancreatic cysts'2017 9,637,779'Antisense transcriptomes of cells'2017 9,580,750'P13K pathway mutations in cancer'2017 9,572,843'Combination bacteriolytic therapy for the treatment of tumors'2017 9,551,037'Consensus coding sequences of human breast and colorectal cancers'2017 9,487,829'Safe sequencing system'2016 9,476,095'Safe sequencing system'2016 9,422,554'MicroRNAome'2016 9,360,526'Methods for beaming'2016 9,353,418'Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma'2016 9,328,343'Method and compositions for detection and enumeration of genetic variations'2016 9,315,868'Diagnostic method using PALB2'2016 9,260,751'Single-molecule PCR on microparticles in water-in-oil emulsions'2016 9,206,467'Tyrosine kinome'2015 9,115,403'Diagnostic method using PALB2'2015 9,012,145'Protein tyrosine phosphatase mutations in cancers'2015 8,901,100'Tumor-specific delivery of therapeutic agents via liposomase'2014 8,859,206'Digital amplification'2014 8,741,573'Consensus coding sequences of human breast and colorectal cancers'2014 8,715,934'Single-molecule PCR on microparticles in water-in-oil emulsions'2014 8,709,723'Integrated analyses of breast and colorectal cancers'2014 8,691,186'Imaging infection with compounds that bind to thymidine kinase'2014 8,685,660'Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma'2014 8,669,062'Disease detection by digital protein truncation assays'2014 8,613,917'Combination bacteriolytic therapy for the treatment of tumors'2013 8,586,725'MicroRNAome'2013 8,568,708'Tumor-specific delivery of therapeutic agents via liposomase'2013 8,444,963'Tumor specific delivery of therapeutic agents via liposomase'2013 8,394,598'Tyrosine kinome'2013 8,273,326'Imaging infection with compounds that bind to thymidine kinase'2012 8,110,356'Method for generating hypermutable plants'2012 8,048,627'Method and compositions for detection and enumeration of genetic variations'2011 8,039,210'Protein tyrosine phosphatase mutations in cancers'2011 8,029,764'Methods for detection of colorectal cancer'2011 8,026,053'Mutations of the PIK3CA gene in human cancers'2011 8,007,782'Combination bacteriolytic therapy for the treatment of tumors'2011 7,915,015'Digital amplification'2011 7,910,300'Disease detection by protein truncation assays'2011 7,892,832'Methods for generating hypermutable microbes'2011 7,829,338'Method for generating hypermutable organisms'2010 7,824,889'Digital amplification'2010 7,785,564'Design and synthesis of renal dipeptidase inhibitors'2010 7,759,121'Methods for generating hypermutable yeast'2010 7,745,165'Phosphatase associated with metastasis'2010 7,704,689'Method for generating hypermutable plants'2010 7,704,687'Digital karyotyping'2010 7,695,969'Methods for generating hypermutable microbes'2010 RE040948'APC antibodies'2009 7,514,216'Methods for generating hypermutable yeast'2009 7,504,493'Characterization of the yeast transcriptome'2009 7,402,660'Endothelial cell expression patterns'2008 7,402,570'Amplification of human MDM2 gene in human tumors'2008 7,393,932'Endothelial cell expression patterns'2008 7,358,351'Endothelial cell expression patterns'2008 7,354,703'Securin is required for chromosomal stability in human cells'2008 7,344,710'Combination bacteriolytic therapy for the treatment of tumors'2008 7,326,778'Mutator gene and hereditary non-polyposis colorectal cancer'2008 7,319,036'Method for generating hypermutable organisms'2008 7,297,837'Method for generating hypermutable organisms'2007 7,267,955'Method for detecting loss of wild-type p53'2007 7,148,009'Cancer drug screen based on cell cycle uncoupling'2006 7,087,583'Sequence specific DNA binding by p53'2006 7,045,352'Converting diploidy to haploidy for genetic diagnosis'2006 7,026,119'Methods for generating hypermutable microbes'2006 RE038916'APC Antibodies'2005 6,926,890'Non-invasive approach for assessing tumors in living animals'2005 6,927,212'Design and synthesis of renal dipeptidase inhibitors'2005 6,921,666'Methods for generating hypermutable yeast'2005 6,900,370'Method for generating hypermutable plants'2005 6,825,038'Method for generating hypermutable organisms'2004 6,800,617'Methods for restoring wild-type p53 gene function'2004 6,753,147'Digital amplification'2004 6,750,021'Subtle mitochondrial mutations as tumor markers'2004 6,746,845'Method for serial analysis of gene expression'2004 6,740,523'14-3-3 arrests the cell cycle'2004 6,677,312'Methods for restoring wild-type p53 gene function'2004 6,656,736'Methods for generating hypermutable yeast'2003 6,610,477'Human DNA mismatch repair proteins'2003 6,605,433'Mitochondrial dosimeter'2003 RE038168'Mono-allelic mutation analysis for identifying germline mutations'2003 6,511,818'Cancer drug screen based on cell cycle uncoupling'2003 6,511,799'CDX2 is downstream mediator of APC tumor suppressor activity'2003 6,498,013'Serial analysis of transcript expression using MmeI and long tags'2002 6,475,794'Converting diploidy to haploidy for genetic diagnosis'2002 6,455,498'Structural alterations of the EGF receptor genes in human tumors'2002 6,440,706'Digital amplification'2002 6,432,640'P53-induced apoptosis'2002 6,419,896'Non-invasive approach for assessing tumors in living animals'2002 6,413,727'Diagnosis for mutant APC by immunoassay'2002 6,399,755'Products for inhibiting expression of human MDM2'2002 6,399,374'Converting diploidy to haploidy for genetic diagnosis'2002 6,383,743'Method for serial analysis of gene expression'2002 6,344,322'Subtle mitochondrial mutations as tumor markers'2002 6,335,156'14-3-3 arrests the cell cycle'2002 6,333,152'Gene expression profiles in normal and cancer cells'2001 6,300,059'Cancer diagnosis and WAF1'2001 6,255,464'Mad-related genes in the human'2001 6,245,515'Sequence specific DNA binding p53'2001 6,225,441'Human fast-1 protein'2001 6,214,616'Homozygous p53 gene-defective human colonic cell line'2001 6,177,251'Method for detection of target nucleic acid by analysis of stool'2001 6,146,894'Method for generating hypermutable organisms'2000 6,140,052'cMYC is regulated by Tcf-4'2000 6,127,126'Method for diagnosing glioma associated with structural alterations of the EGF receptor gene in human tumors'2000 6,114,124'Detection of APC proteins'2000 6,110,738'Human fast-1 gene'2000 6,100,032'Human Smad3 and Smad4 are sequence-specific transcription activators'2000 6,090,566'Diagnostic method detecting loss of wild-type p53'2000 RE036713'APC gene and nucleic acid probes derived therefrom'2000 6,054,570'Selective expression of desired genes in cells expressing oncoproteins'2000 6,048,701'Antibody detection of mismatch repair proteins'2000 6,013,461'APC mutation associated with familial colorectal cancer in Ashkenazi Jews'2000 5,981,725'Structural alterations of the EGF receptor gene in human tumors'1999 5,955,263'Sequence specific DNA binding by p53'1999 5,922,576'Simplified system for generating recombinant adenoviruses'1999 5,910,418'Antibodies and assay for detecting mutant APC proteins'1999 5,910,407'Method for detection of target nucleic acid by analysis of stool'1999 5,897,999'Cancer drug screen based on cell cycle uncoupling'1999 5,888,735'Cancer drug screen based on cell cycle uncoupling'1999 5,882,865'Cancer drug screen based on cell cycle uncoupling'1999 5,879,889'Cancer drug screen based on cell cycle upcoupling'1999 5,879,890'APC mutation associated with familial colorectal cancer in Ashkenazi jews'1999 5,874,235'Screening assays for cancer chemopreventative agents'1999 5,874,545'DCC antibodies'1999 5,871,968'P21.sup.WAF1 derivatives and diagnostic methods'1999 5,871,925'Tumor classification as indication of hereditary non-polyposis colorectal carcinoma'1999 5,866,340'Selective expression of desired genes in cells expressing oncoproteins'1999 5,866,330'Method for serial analysis of gene expression'1999 5,858,976'Methods for inhibiting interaction of human MDM2 and p53'1999 5,851,775'.beta.-catenin, Tcf-4, and APC interact to prevent cancer'1998 5,843,757'Human JTV1 gene overlaps PMS2 gene'1998 5,837,443'Diagnostic method employing MSH2 protein'1998 5,834,190'Chromosome 18Q loss and prognosis in colorectal cancer'1998 5,830,676'Diagnosis with MCC'1998 5,814,317'Structural alterations of the EGF receptor gene in human gliomas'1998 5,807,692'P21WAF1 derivatives and diagnostic methods'1998 5,783,666'APC (adenomatous polyosis coli) protein'1998 5,760,207'Primers for amplifying APC gene sequences'1998 5,756,455'Amplification of human MDM2 gene in human tumors'1998 5,750,352'Mono-allelic mutation analysis for identifying germline mutations'1998 5,736,389'EBI nucleic acids'1998 5,736,338'Method of diagnosing Neoplastic disease by detecting increased expression of human MDM2 protein'1998 5,728,523'Polymerase delta mutations in colorectal tumors with replication errors'1998 5,709,998'Molecular diagnosis of familial adenomatous polyposis'1998 5,710,010'Assays for the presence of a mutant EGF receptor'1998 5,708,136'Polypetides which bind to human MDM2'1998 5,702,903'Method and cells for drug identification'1997 5,702,886'Chromosome I8Q loss and prognosis in colorectal cancer'1997 5,700,657'Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby'1997 5,695,937'Method for serial analysis of gene expression'1997 5,693,470'Diagnostic method employing MSH2 nucleic acids'1997 5,693,536'Gene therapy with MCC'1997 5,691,454'APC antibodies'1997 5,650,281'Diagnosis using DCC gene'1997 5,648,212'Detection of inherited and somatic mutations of APC gene in colorectal cancer of humans'1997 5,618,921'Antibodies for detection of human MDM2 protein'1997 5,606,044'Kits for detecting amplification of human MDM2'1997 5,602,243'DCC probes, primers, and kits'1997 5,591,826'Human MSH2 protein'1997 5,580,729'Generalized method for cancer assessment'1996 5,576,422'MCC protein and antibody'1996 5,571,905'Gene mutated in colorectal cancer of humans'1996 5,561,223'DCC protein'1996 5,550,023'Amplification of human MDM2 gene in human tumors'1996 5,532,108'Gene deleted in colorectal cancer of humans'1996 5,527,676'Detection of loss of the wild-type P53 gene and kits therefor'1996 5,519,118'Human MDM2 protein involved in human tumors'1996 5,492,808'Means for detecting familial colon cancer (FCC)'1996 5,420,263'Amplification of human MDM2 gene in human tumors'1995 5,411,860'Amplification of human MDM2 gene in human tumors'1995 5,401,828'Structural alterations of the EGF receptor gene in human gliomas'1995 5,380,645'Generalized method for assessment of colorectal carcinoma'1995 5,362,623'Sequence specific DNA binding by p53'1994 5,352,775'APC gene and nucleic acid probes derived therefrom'1994 5,330,892'MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans'1994 5,212,290'Antibodies specific for type II mutant EGTR'1993

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1993–2021Patents assigned to UNIV JOHNS HOPKINS (192)· patent assignee history

1993–2021Patents assigned to UNIV DUKE (16)· patent assignee history

1993–2021Based in Baltimore, MD, US· patent location history

1994–2009Patents assigned to UNIV UTAH (13)· patent assignee history

2012–2018Patents assigned to VOGELSTEIN BERT (27)· patent assignee history

2012–2018Patents assigned to KINZLER KENNETH W (24)· patent assignee history

2017Based in Balitmore, MD, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
UNIV JOHNS HOPKINS	192	1993–2021
VOGELSTEIN BERTself	27	2012–2018
KINZLER KENNETH W	24	2012–2018
UNIV DUKE	16	1993–2021
UNIV UTAH	13	1994–2009

Locations

Location	Patents	Span
Baltimore, Maryland, US	206	1993–2021
Balitmore, Maryland, US	1	2017